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Abstract
Background: HIV-1 Gag proteins are essential for virion assembly and viral replication in newly
infected cells. Gag proteins are also strong determinants of viral infectivity; immune escape
mutations in the Gag capsid (CA) protein can markedly reduce viral fitness, and interactions of CA
with host proteins such as cyclophilin A (CypA) and TRIM5α can have important effects on viral
infectivity. Little information, however, is available concerning the extent that different primary Gag
proteins affect HIV-1 replication in different cell types, or the impact on viral replication of
differences in the expression by target cells of proteins that interact with CA. To address these
questions, we compared the infectivity of recombinant HIV-1 viruses expressing Gag-protease
sequences from primary isolates in different target cells in the presence or absence of agents that
disrupt cyclophilin A – CA interactions and correlated these results with the viral genotype and the
expression of cyclophilin A and TRIM5α by the target cells.
Results: Viral infectivity was governed by the nature of the Gag proteins in a target cell-specific
fashion. The treatment of target cells with agents that disrupt CypA-CA interactions often
produced biphasic dose-response curves in which viral infectivity first increased and subsequently
decreased as a function of the dose used. The extent that treatment of target cells with high-dose
CypA inhibitors impaired viral infectivity was dependent on several factors, including the viral
genotype, the nature of the target cell, and the extent that treatment with low-dose CypA
inhibitors increased viral infectivity. Neither the presence of polymorphisms in the CA CypA-
binding loop, the level of expression of CypA, or the level of TRIM5α expression could, alone,
explain the differences in the shape of the dose-response curves observed or the extent that high-
dose CypA inhibitors reduced viral infectivity.
Conclusion: Multiple interactions between host-cell factors and Gag can strongly affect HIV-1
infectivity, and these vary according to target cell type and the origin of the Gag sequence. Two of
the cellular activities involved appear to be modulated in opposite directions by CypA-CA
interactions, and Gag sequences determine the intrinsic sensitivity of a given virus to each of these
cellular activities.
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Background
The HIV-1 Gag proteins play important roles throughout
the viral life-cycle, including the assembly and release of
viral particles, their subsequent maturation into infectious
virions, and during the events occurring between the
release of capsids into newly infected cells and the integra-
tion of proviral DNA. During the early steps of the viral
life cycle, viral proteins, especially capsid (CA), are in inti-
mate contact with the intracellular environment. Consid-
erable evidence supports the idea that interactions
between host cellular proteins and the viral capsid are
important for events occurring early in infection, such as
the transport of the preintegration complex, uncoating of
the capsid, nuclear entry, and integration (reviewed in [1-
4]).
A striking example of such interactions is that occurring
between the capsid and the abundant intracellular protein
cyclophilin A (CypA), a peptidyl-prolyl isomerase whose
active site binds a proline residue present in an exposed
loop extending from the CA subunits [5,6]. Several lines
of evidence indicate that the inhibition of CypA-CA inter-
actions in newly infected human target cells usually
impairs viral infectivity, including studies evaluating the
infection of target cells whose CypA expression has been
reduced or eliminated, the effect of inhibiting CypA-CA
interactions using cyclosporine A (CsA) or its analogs, and
the impact on infectivity of CA mutations such as P90A
and G89A that impair CypA binding [5,7-15]. Although
inhibition of CypA-CA interactions has generally been
found to be deleterious to HIV-1 replication in human
cells, exceptions have been reported. Viruses carrying CA
mutations selected during viral replication in CsA-treated
target cells (A92E, G94D) and a mutation produced
through alanine scanning (T54A) replicate better in some,
but not all, target cells in the presence of CsA [10,11,16-
18]. Because these mutants continue to bind CypA, the
results indicate that CypA binding can also be detrimental
to HIV-1 replication in a virus-specific and target cell-spe-
cific fashion. The mechanisms through which CypA bind-
ing modulates viral infectivity are not defined and several
possibilities have been discussed, including effects on cap-
sid stability, viral uncoating, and the protection of viral
cores from cellular restriction factors [8,19-23].
The HIV-1 CA is also known to be targeted by host cell
restriction factors, including the well characterized
TRIM5α protein and the activity designated as Lv2
[7,9,24-33]. Although human TRIM5α can inhibit the
replication of a variety of retroviruses to various extents
(N-MLV, EIAV, HIV-2, FIV, SIVmac), it displays only mod-
est activity against HIV-1 [7,34-41]. Interestingly, human
TRIM5α is more active against HIV-1 expressing the G89V
mutation than against wild-type HIV-1 [39], but less
active against viruses carrying certain polymorphisms in
the CypA binding loop [21,24,27,30,42-44], consistent
with the possibility that CypA binding may modulate the
activity of human TRIM5α.
The viral strain-dependent effects of CypA and TRIM5α
interactions described above underscore the potential
importance of Gag polymorphisms on HIV-1 replication
capacity. In particular, it has been well documented that a
number of Gag mutations selected in response to immune
pressure can be deleterious to viral replication [45-47]. It
remains unclear, however, whether these polymorphisms
modify intrinsic properties of the capsid structure or influ-
ence the ability of Gag proteins to interact with host cellu-
lar proteins. Because the expression of cellular proteins
that can interact with the viral capsid is likely to differ in
different cell types, the finding that the replicative capacity
of a virus expressing a given gag gene is cell-type depend-
ent would support the later possibility. Furthermore, little
information is available on the replication of viruses
expressing Gag proteins derived from primary HIV-1 iso-
lates in different cell types, and the replicative impact of
the level of expression of cellular proteins that interact
with viral capsids from such viruses is unknown.
To address these questions, we compared the infectivity of
recombinant HIV-1 viruses expressing Gag-protease (Gag-
PR) sequences from primary isolates in different target
cells in the presence or absence of agents that disrupt
CypA-CA interactions and correlated these results with the
viral genotype and the expression of CypA and TRIM5α by
the target cells. Our results indicate that viral infectivity is
governed by the nature of the Gag proteins in a target cell-
specific fashion. The treatment of target cells with agents
that disrupt CypA-CA interactions often produce biphasic
dose-response curves in which viral infectivity first
increased, and subsequently decreased as a function of the
dose used. The extent that treatment of target cells with
high-dose CypA inhibitors impairs viral infectivity is
dependent on several factors, including the viral geno-
type, the nature of the target cell, and the extent that treat-
ment with low-dose CypA inhibitors increased viral
infectivity. Neither the presence of polymorphisms in the
CA CypA-binding loop, the level of expression of CypA, or
the level of TRIM5α expression could, alone, explain the
differences in the shape of the dose-response curves
observed or the extent that high-dose CypA inhibitors
reduced viral infectivity. We conclude from these observa-
tions that the impact of CypA antagonists on viral infectiv-
ity is multi-factorial and may reflect both the relative
abundance and the viral susceptibility to two cellular
activities, whose effect on HIV-1 infectivity is modulated
in opposite directions by CypA-CA interactions.Retrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
Page 3 of 15
(page number not for citation purposes)
Results
Infectivity of recombinant viruses in different target cells
We created a series of pNL4-3 based recombinant viruses
in which the Gag-PR sequences were derived from clinical
isolates obtained from patients who had never received
protease inhibitors, and in which a sequence coding
Renilla luciferase was inserted in place of Nef. In each case,
proviruses expressing the NL4-3 (X4-tropic) envelope as
well as envelope-deleted versions were produced. In ini-
tial studies, VSV-pseudotyped envelope-deleted viruses
were used to infect different target cells, and 40 hours
later, infectivity was assessed by measuring luciferase
expression.
The amount of luciferase activity produced was cell-type
dependent. Thus, for a given virus, greater luciferase activ-
ity was always observed using U373-X4 cells than in MT4-
R5 cells or P4 cells (compare Figures 1A–C). In addition,
some viruses appeared to have generally good (NL4-3) or
poor infectivity (NRC10). Nevertheless, by comparing the
ratio of luciferase activity in two different cell types it was
clear that the relative infectivity of these viruses for differ-
ent cell types could be quite different. For example, the
ratio of luciferase activities observed in U373-X4 cells/
MT4-R5 cells was elevated and not significantly different
for the viruses NRC1 and NRC9 (Figure 1D), but the ratio
of luciferase activities observed in P4 cells/MT4-R5 cells
was significantly lower for NRC1 than for NRC9 (p <
0.001, Figure 1E), whereas the ratio of luciferase activities
observed in U373-X4 cells/P4 cells was significantly
greater for NRC1 than NRC9 (p < 0.001, Figure 1F). Thus,
the Gag-Pol sequences expressed by NRC1 promoted rep-
lication in U373-X4 cells relative to that in P4 cells,
whereas the converse was true for NRC9.
Similarly, the U373-X4/MT4-R5 and U373-X4/P4 ratios
were greater for NRC2 than for NRC10 (p < 0.05 for both
comparisons). In contrast, the P4/MT4-R5 ratios for
NRC2 and NRC10 were not significantly different, con-
sistent with the idea that the gag-pol sequences expressed
by NRC2 were more favorable to replication in U373-X4
cells than those expressed by NRC10. Very similar results
were obtained when recombinant viruses expressing the
NL4-3 envelope were used in the place of VSV-pseudo-
typed viruses (data not shown), suggesting that the entry
pathway did not have a major impact on these cell-type
specific differences in infectivity.
To evaluate the impact of mutations that impair protease
activity on the relative infectivity of viruses in different cell
types, we also evaluated a recombinant virus (GPCA) that
expresses the same Gag sequence as NL4-3, but contains 3
resistance mutations in the protease that reduce infectivity
to 20% of that of NL4-3 (Figures 1A–C). The relative infec-
tivity of GPCA in different cell types was not significantly
different from that of NL4-3 (Figures 1D–F).
Taken together, these findings indicate that: i) target cells
differentially express activities that modulate viral infec-
tivity, and that ii) the impact of these activities on infectiv-
ity varies as a function of the Gag-PR sequences expressed
by the viruses.
Effect of cyclophilin inhibitors on viral infectivity in 
different target cells
Previous studies have indicated that interactions between
viral capsid and cyclophilin A can modulate viral infectiv-
ity. To further characterize the activities expressed by dif-
ferent target cells that influence viral infectivity, we
evaluated the impact of the disruption of capsid-CypA
interactions on the infectivity of the 7 different recom-
binant viruses in 5 different target cell types. The results
obtained using the CsA analog Debio-025 are shown in
Figure 2. A variety of response profiles were observed,
depending on both which recombinant virus was evalu-
ated and the nature of the target cell. When MT4-R5 cells
were used as target cells, treatment with increasing doses
between 0.16 nM and 40 nM Debio-025 led to a progres-
sive decrease in infectivity. At higher doses infectivity
often reached an apparent plateau level that could differ
for different viruses (e.g., the infectivities of NRC10 and
NRC2 in cells treated with 5 μM Debio-025 were, respec-
tively, 29.3 ± 12.3% and 14.0 ± 6.8% of that observed in
untreated cells, p < 0.03 by t-test).
When U373-X4 cells were used as target cells, the infectiv-
ity of some viruses (NRC3-1, NRC3-5, NRC2, NRC10)
increased by more than 50% following treatment with 1.6
– 8 nM Debio-025 (p < 0.04 – 0.01). In U373-X4 cells
treated with higher doses of Debio-025 (40 nM – 5 μM),
the infectivity of all viruses except NRC1 decreased signif-
icantly compared to that observed in cells treated with 8
nM Debio-025. At the highest doses of Debio-025 tested
(5 μM), the percent residual infectivity of each virus in
U373-X4 cells was always significantly higher than that
observed with similarly treated MT4-R5 cells, but varied
from 25.6 ± 12.0% (NL4-3) to 105.8 ± 22.5% (NRC10) of
that observed in untreated U373-X4 cells.
When HeLa-derived P4 cells, CEM cells and H9 cells were
used as targets, the profiles of infectivity generally fell in
between those seen for MT4-R5 cells and U373-X4 cells.
Following treatment with low doses of Debio-025, signif-
icant increases in infectivity were observed using CEM and
H9 cells for several viruses, but the magnitude of this
effect was less striking than that seen in U373-X4 cells. At
higher doses, infectivity in CEM, H9 and P4 cells
decreased for all viruses except NRC1. The extent of inhi-
bition observed in these cell types following pretreatmentRetrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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Infectivity of recombinant viruses in different cell types Figure 1
Infectivity of recombinant viruses in different cell types. (A-C) The indicated target cells were cultured overnight in 96-
well plates, infected with serial dilutions of supernatants containing each of the 7 indicated VSV pseudotyped envelope-deleted 
recombinant viruses (final concentrations 0.156 – 10 ng p24/ml), and luciferase activity (RLU) expressed by the target cells was 
determined 40 h after infection. The slope of the dose response curve was determined by linear regression. The slope 
obtained from infection of target cells by NL4-3 was measured on each 96-well plate, and the value used to normalize the slope 
of the other samples present on that plate, as described in the Materials and Methods. The results shown are the mean ± SEM 
for 4 independent experiments. (D-E) For each experiment, the results were also expressed as a ratio of the normalized slopes 
obtained for the two indicated target cell types. The results shown are the mean ± SEM for 4 independent experiments.
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Effect of Debio-025 on the infectivity of recombinant viruses Figure 2
Effect of Debio-025 on the infectivity of recombinant viruses. Target cells, [U373-X4 (filled green circles), P4 cells 
(open black circles), MTR-R5 cells (filled red circles), CEM cells (filled purple circles), and H9 cells (filled blue circles)] were cul-
tured in the presence of serial dilutions of Debio-025 and infected with 100 ng p24/ml (all recombinant viruses except NL4-3) 
or 20 ng p24/ml (NL4-3) of the indicated recombinant viruses. Luciferase activity (RLU) expressed by target cells was deter-
mined 40 h after infection. The results are expressed as a percentage of luciferase activity in cells cultured in the absence of 
Debio-025. As indicated in the Materials and Methods, several dilution schemes were used in the course of these studies; each 
data point represents pooled data for cells incubated the presence of a range of concentrations of Debio-025 as follows: 5 μM 
(2–5 μM), 1 μM (0.5–1 μM); 200 nM (125–200 nM); 40 nM (30–40 nM); 8 nM (8–10 nM); 1.6 nM (1.6 nM). The results shown 
are the mean ± SEM for 6 independent experiments (U373-X4, P4, MT4-R5) or 3 independent experiments (CEM, H9).
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with 5 μM Debio-025, however, was often less than that
observed in similarly treated MT4-R5 cells. For most
viruses, the inhibition of infectivity in CEM, H9 and P4
cells pretreated with 5 μM Debio-025 was greater than
that observed in similarly treated U373-X4 cells, but
exceptions were observed (e.g., NL4-3 and NRC9 in P4
cells, NRC9 in CEM cells).
Similar studies were performed using using the CypA
inhibitor CsA. As shown in Figure 3, the profiles were gen-
erally similar to those observed using Debio-025, except
that the curves were shifted to the right. When U373-X4
cells were used as target cells, the infectivity of the same 4
viruses (NRC3-1, NRC3-5, NRC2, NRC10) increased by
more than 50% following treatment with 100 nM CsA.
The dose of CsA required for maximal increase in the
infectivity of these viruses, however, was more than 10-
fold higher than that required for Debio-025 (8 nM). For
each virus, the extent of inhibition of viral infectivity
observed in U373-X4 cells and MT4-R5 cells treated with
2 μM CsA was generally similar to that seen when these
cells were treated with 5 μM Debio-025. Consistent with
the lower potency of CsA, evidence of an inhibitory pla-
teau frequently observed in Debio-025 treated cells was
usually less evident for CsA-treated cells.
The Debio-025 and CsA dose-response curves for GPCA,
the virus expressing the same gag sequence as NL4-3 but
containing protease mutations that impair infectivity,
were very similar to those obtained for NL4-3.
Relationship between the effect of low-dose and high-dose 
Debio-025 on viral infectivity
For several viruses, as shown above, the effect of treatment
of certain target cells with Debio-025 on infectivity gave
biphasic dose-response curves in which viral infectivity
first increased and then subsequently decreased as a func-
tion of the dose of Debio-025 used. To examine the pos-
sibility that the increase in infectivity observed in cells
treated with low-dose Debio-025 might influence the
extent of inhibition observed when cells were treated with
high-dose Debio-025, regression analyses were performed
for each virus. As illustrated for NRC10 in Figure 4, a
direct correlation was observed comparing the infectivity
observed at 8 nM Debio-025 and that observed with 5 μM
Debio-025 (r2 = 0.91, p < 0.02). Overall, for the 4 viruses
displaying a more than 50% increase in infectivity in at
least one target cell type treated with 8 nM Debio-025
(NRC3-1, NRC3-5, NRC10, NRC2), significant positive
correlations were observed in 3 cases (r2 0.86 – 0.92; p <
0.01 – 0.03), and for the fourth virus (NRC2), a relatively
strong correlation was also seen although it did not
achieve statistical significance (r2 = 0.66, p = 0.09). It is
also noteworthy that among the target cells tested, MT4-
R5 cells were the only target cells in which a significant
increase in infectivity was not observed for any of the
viruses following treatment with 8 nM Debio-025.
Indeed, for all viruses except NRC1, treatment of MT4-R5
cells with 8 nM Debio-025 led to a significant decrease in
viral infectivity, ranging from 18.4% for NRC2 to 45.2%
for NRC10.
Cyclophilin A expression in target cells
Previous studies have suggested that the level of expres-
sion of CypA in target cells may influence the effect of CsA
or CsA analogs on viral infectivity [11,21,48-50]. To
explore this relationship for the target cells and viruses
evaluated in this study, we measured CypA expression at
both the mRNA and protein level. CypA mRNA expres-
sion relative to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) varied over a 5.6-
fold range (Figure 5A). At the mRNA level, the expression
of CypA was significantly higher in both P4 and U373-X4
cells than in CEM cells or MT4-R5 cells (p < 0.05 – 0.01
for all comparisons). At the protein level, CypA expression
varied over only a 2-fold range (Figure 5B). CypA expres-
sion per milligram of protein was significantly higher in
both P4 and U373-X4 cells than in CEM cells, MT4-R5
cells or H9 cells (p < 0.01 for all comparisons).
The comparison of the results of CypA expression (Figure
5) and the dose-response curves for Debio-025 and CsA
(Figures 2 and 3, respectively) did not support the conclu-
sion that differences in cellular CypA levels could explain
the occurrence of biphasic responses in some, but not all,
cell types. Despite the fact that, CypA expression in U373-
X4 and P4 cells was not significantly different at either the
mRNA or protein level, treatment of U373-X4 cells with 8
nM Debio-025 led to a greater than 50% increase in infec-
tivity for 4/8 viruses tested. In contrast, increases of this
magnitude were never seen in P4 cells. Conversely, fol-
lowing pretreatment with 8 nM Debio-025, significant
increases in infectivity were observed for some viruses in
H9 and/or CEM cells, despite the fact that CypA expres-
sion was lower in these cell types than in P4 cells.
CypA expression also did not appear to explain the extent
that treatment of target cells with high-dose Debio-025
reduced viral infectivity. As noted above, treatment of cells
with doses greater than 200 nM Debio-025 resulted in an
apparent plateau effect, suggesting that CA-CypA interac-
tions had been completely inhibited in all cell types at
doses above 100 nM. Nevertheless, the extent of inhibi-
tion of infectivity of several viruses (e.g. NRC9, NRC3-5)
could be similar in cell types expressing different levels of
CypA, and inhibition by high-dose Debio-025 was often
greatest in MT4-R5 cells, the cell line that expressed the
lowest levels of CypA.Retrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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Effect of cyclosporine A on the infectivity of recombinant viruses Figure 3
Effect of cyclosporine A on the infectivity of recombinant viruses. Target cells, [U373-X4 (filled green circles), P4 cells 
(open black circles), MTR-R5 cells (filled red circles), CEM cells (filled purple circles), and H9 cells (filled blue circles)] were cul-
tured in the presence of the indicated serial dilutions of CsA and infected with 100 ng p24/ml (all recombinant viruses except 
NL4-3) or 20 ng p24/ml (NL4-3) of the indicated recombinant viruses. Luciferase activity (RLU) expressed by target cells was 
determined 40 h after infection. The results are expressed as a percentage of luciferase activity in cells cultured in the absence 
of CsA. The results shown are the mean ± SEM for 6 independent experiments (U373-X4, P4, MT4-R5) or 3 independent 
experiments (CEM, H9).
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TRIM5α expression in target cells
We also evaluated the expression of the restriction factor
TRIM5α at the mRNA level. TRIM5α mRNA expression
relative to GAPDH varied over a 5-fold range (Figure 6).
The TRIM5α/GAPDH ratio was significantly lower in
MT4-R5 cells than in the other four target cells evaluated
(p < 0.01 – 0.05). CypA mRNA levels were considerably
higher than TRIM5α mRNA levels in all cell types, ranging
from 86-fold (CEM cells) to 275-fold (H9 cells).
Because TRIM5α expression was similar in all target cell
types except MT4-R5 cells, these findings do not support
the idea that differences in TRIM5α expression explain the
occurrence of biphasic dose-response curves in some, but
not all, target cells. The greatest inhibition by high-dose
Debio-025 usually occurred in MT4-R5 cells, the cell line
that had the lowest TRIM5α/GAPDH ratio.
Genotype-phenotype correlations
The amino acid sequences of the CA proteins surrounding
the CypA binding loop for the 7 viruses are shown in
Table 1. The infectivity of NRC1 was not modified after
treatment of most target cells with Debio-025, although
infectivity did decrease significantly in MT4-R5 cells.
NRC1 expressed mutations in and near the CypA binding
loop (V86A/H87Q/I91V/M96L) at positions that have
been shown to confer CypA resistance in several previous
studies [21,24,27,30,42-44]. NRC9 also expressed two of
these mutations. The infectivity of this virus was inhibited
in Debio-025 treated cells, but the extent of inhibition of
this virus in Debio-025 treated MT4-R5 cells was less than
that observed for the other viruses studied. Viruses dem-
onstrating more that a 50% increase in infectivity in target
cells treated with 8 nM Debio-025 had two (NRC10), one
(NRC2) or no mutations (NRC3-1, NRC3-5) in the CypA
binding loop, although it is perhaps noteworthy that the
later two viruses did have the L83V mutation in a residue
adjacent to this region.
Mutations outside of the CypA binding loop have been
shown to modify the sensitivity of viruses to CypA inhib-
itors, including T54A, A105T, T110N, N121S and R132K
[18,27,45,46]. None of the viruses studied here carried
mutations at positions 54, 105 or 121. NRC1 expressed
the T110N mutation, a T-cell epitope escape mutation in
HLA-B57+ individuals that can reduce infectivity and
increase sensitivity to CsA. As indicated above, however,
this virus also expressed compensatory mutations in the
CypA binding loop that restore infectivity and impart CsA
resistance to viruses carrying the T110N mutation [45].
One virus (NRC10) expressed the R132K and L136M
mutations, T-cell epitope escape mutations in HLA-B27+
individuals that cause an impairment in viral replication
in CEM cells that can be partially restored by culturing tar-
get cells with 0.5 μM CsA [46]. In our studies, NRC10 did
show poor infectivity in all target cells tested. Although
viral infectivity was inhibited by treatment of most cell
types with high-dose CsA and Debio-025, it was one of
four viruses that demonstrated biphasic dose response
curves, consistent with the possibility that the R132K
mutation contributed to this phenotype for this virus.
Discussion
This study, comparing the infectivity of recombinant HIV-
1 viruses expressing Gag-PR sequences from primary iso-
lates in different target cells in the presence or absence of
agents that disrupt CypA-CA interactions, established sev-
eral interesting points: i) viral infectivity is governed both
by the nature of the Gag proteins expressed and the nature
of the target cells; ii) the treatment of target cells with
Debio-025 or CsA often produces biphasic dose-response
curves; iii) the extent that treatment of target cells with
high-dose CypA inhibitors impairs viral infectivity is
dependent on several factors, including the virus used, the
nature of the target cell, and the extent that treatment with
low-dose CypA inhibitors increased viral infectivity; and
iv) neither the level of expression of CypA nor the level of
TRIM5α could, alone, explain the differences in the shape
of the dose-response curves observed or the extent that
high-dose CypA inhibitors reduced viral infectivity. Each
of these observations is discussed below.
The relative infectivity of the recombinant HIV-1 viruses
evaluated here in different cell types and in different con-
ditions was clearly influenced by the primary Gag-PR
sequence expressed by the virus. In these studies, we chose
Relationship between the viral infectivity in cells treated with  low-dose and high-dose Debio-025 Figure 4
Relationship between the viral infectivity in cells 
treated with low-dose and high-dose Debio-025. The 
infectivity of the recombinant virus NRC-10 in cells treated 
with 8 nM Debio-025 (low-dose Debio-025) is plotted as a 
function of the infectivity in cells treated with 5 μM Debio-
025 (high-dose Debio-025) for each of the indicated target 
cells. The linear regression for these results is also shown (r2 
= 0.91, p < 0.02).
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CypA expression in target cells Figure 5
CypA expression in target cells. (A) CypA mRNA levels, expressed as copies per 1000 copies of GAPDH mRNA, were 
determined by real-time PCR using primers and probes shown in Table 2. Results are the mean ± SEM for 3 independent 
experiments using different cell pellets. (B) CypA protein expression. Equal amounts of soluble cell protein were electro-
phoresed into 10% SDS-PAGE gels, and transferred to PVDF membranes. The blots were probed sequentially with a rabbit 
anti-cypA antibody and a IRDye 800CW-conjugated donkey anti-rabbit IgG antibody. The blots were scanned using an Odyssey 
Infrared imaging system, and fluorescence intensity was analysed using Odyssey application software. Lysates from P4 cells 
were included in each gel, and the intensities of the CypA bands in the other samples on the same gel were expressed relative 
to that observed for P4 cells. The results presented are the mean ± SEM for 4 independent experiments, all performed using 
different cell suspensions.
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to use recombinant viruses expressing both Gag and pro-
tease sequences from the primary isolate to ensure that all
Gag proteins expressed by the recombinant viruses were
derived from the primary isolate (including the C-termi-
nal region of p6), and to ensure optimal compatibility
between the protease and its Gag substrate. Although pol-
ymorphisms in the protease could also modify viral infec-
tivity, it is most likely that the cell type-dependent
differences in infectivity seen in our experiments reflect
differences in Gag proteins. First, the primary isolates were
obtained from patients with no exposure to protease
inhibitors. Second, a NL4-3 derived virus carrying 3 muta-
tions in protease (L10I, G48V, V82A) that reduced viral
infectivity by 5-fold had no significant impact on either
the relative infectivity in different cell types, or on the pro-
files of the dose-response curves obtained using CypA
inhibitors compared to those observed for wild-type NL4-
3. These results support the conclusion that the target cells
used in this study differentially express factors whose abil-
ity to modify viral infectivity is dependent on the structure
of the Gag proteins expressed by the virus, not differences
in protease activity.
A striking finding in our study was the observation that
the treatment of target cells with CsA or Debio-025 often
produced biphasic dose-response curves in which infectiv-
ity increased following treatment with low doses of the
CypA inhibitor, but decreased following treatment with
higher doses. The presence and extent of such biphasic
responses were dependent, however, on both the nature
of the virus and the target cell employed. Studies evaluat-
ing the full dose-response curve to CypA inhibitors using
infectivity assays have not been previously reported.
Using other approaches, treatment of target cells with CsA
has been found to increase viral replication in a dose-
dependent and cell-type dependent fashion. For example,
in studies evaluating virus accumulation after multiple
replicative cycles, both Gatanaga et al. and Yin et al.
[21,49] found that the replication of NL4-3 in H9 cells
was improved by treatment with 0.5 μM CsA but not 2.5
μM CsA, whereas both doses inhibited NL4-3 replication
in Jurkat cells and mitogen-stimulated lymphocytes. In
our experiments, both of these doses of CsA inhibited
NL4-3 infectivity in H9 cells. Because multi-cycle viral rep-
lication assays are sensitive not only to effects of CsA on
the early steps of viral replication, as measured in our
experiments, but also to potential effects on viral produc-
tion [51,52] and the infectivity of the viruses released
[10,11,14,53,54], it is not surprising that the two
approaches would not give completely concordant
results. With one possible exception, Ptak et al. [55] did
not observe biphasic dose response curves when the repli-
cation of 18 different viral isolates was evaluated in
Debio-025 treated mitogen-stimulated lymphocytes.
The increase in viral infectivity observed following treat-
ment of certain target cells with low-dose CypA inhibitors
TRIM5α expression in target cells Figure 6
TRIM5α expression in target cells. TRIM5α mRNA lev-
els, expressed as copies per 1000 copies of GAPDH mRNA, 
were determined by real-time PCR using primers and probes 
shown in Table 2. Results are the mean ± SEM for 3 inde-
pendent experiments using different cell pellets.
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Table 1: Sequences of the region surrounding the CypA binding Loop in CA*
Virus Position and Sequence
--- CypA Binding Loop ---
80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
NL4-3 WDR L H P V H A G P I A P GQMR E P R
NRC1 ......A Q ...V....L... .
NRC2 ...........V........ .
NRC3-1 ... V .............. . . .
NRC3-5 ... V ................ .
NRC9 ...... A ....V........ .
NRC10 ...... A .........I... .
*Numbers indicate the amino acid position in the CA protein. The CypA binding loop is indicated in italics [19]. The amino acid sequence for NL4-
3 is given in single letter code. Only amino acids that differ from the NL4-3 sequence are shown for the other viruses.Retrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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is also somewhat reminiscent of responses observed for
HIV-1 carrying the A92E or G94D mutations in CA, muta-
tions that were selected after the in vitro replication of
wild-type virus in CsA-treated target cells [16]. Depending
on the target cell type used, replication of these mutants is
either improved (CsA dependent phenotype) or unmodi-
fied (CsA resistant phenotype) by treating target cells with
CsA [11,16,17,49]. Unlike the responses observed in our
study, however, viral replication of A92E or G94D
mutants was generally better in cells treated with high-
dose CsA than in untreated target cells.
One factor that has been suggested to modulate the effects
of CypA inhibitors in different target cells is the level of
expression of CypA [11,21,48,49]. According to this idea,
a given virus would replicate optimally in the presence of
a limited range of intracellular CypA levels. Thus, in target
cells expressing "excessive" amounts of CypA, the treat-
ment of target cells with increasing concentrations of
CypA inhibitors might result in an initial improvement in
infectivity, followed by a subsequent impairment. Indeed,
Ylinen et al. recently demonstrated that 2–3-fold increases
in CypA expression in TE671 cells can have a profound
impact on the replication of viruses carrying the A92E and
G94D Gag mutations [50]. Several findings in our study,
however, argued forcefully against the idea that differ-
ences in CypA expression, alone, could account for the
presence of biphasic dose-response curves. For a given
virus, biphasic dose-response curves could be present or
absent in target cells expressing similar levels of CypA. For
example, CypA expression in U373-X4 and P4 cells was
not significantly different at either the mRNA or protein
level, but treatment of U373-X4 cells with 8 nM Debio-
025 led to a greater than 50% increase in infectivity for 4/
8 viruses tested, whereas increases of this magnitude were
never seen in P4 cells. In this context, it is noteworthy that
the techniques used in this study to quantify Western
blots could easily distinguish two-fold differences in
CypA levels, indicating that CypA expression in U373-X4
cells and P4 cells was indeed very similar. Similarly, fol-
lowing pretreatment with 8 nM Debio-025, significant
increases in infectivity were observed for some viruses in
H9 and/or CEM cells, but not P4 cells, despite the fact that
CypA expression was significantly lower in these cell types
than in P4 cells.
Differences in CypA expression also did not appear to
explain the extent that treatment of target cells with high-
dose CypA inhibitors inhibited viral infectivity. Treatment
of target cells with 200 nM Debio-025 appeared to com-
pletely inhibit CypA-CA interactions, because further
decreases in viral infectivity were not observed in cells
treated with concentrations in the 200 nM – 5 μM range.
Nevertheless, for a given virus, the extent of inhibition of
viral infectivity could be different in cell types expressing
similar amounts of CypA (e.g., the responses of NL4-3
and NRC10 to Debio-025 in U373-X4 cells and P4 cells),
and inhibition could be similar in cell types expressing
different amounts of CypA (e.g., the responses of NRC3-1
and NRC3-5 to Debio-025 in MT4-R5 cells and P4 cells).
Taken together, these findings indicate that differences in
CypA expression levels, alone, cannot explain the differ-
ences in the dose-response curves observed in our study,
but do not exclude a role for CypA levels in modulating
these responses.
Our results are consistent with previous studies showing
that the modulation of the activity of the restriction factor
TRIM5α does not explain the inhibition of viral infectivity
in cells treated with high-dose CypA inhibitors. We found
that the greatest inhibition of viral replication by target
cells treated with high-dose CypA inhibitors occurred in
MT4-R5 cells, the cell type expressing the lowest levels of
TRIM5α at the mRNA level. Others have shown that
human TRIM5α has only modest activity against HIV-1
even after over-expression [7,29,34-36,56]; depleting
TRIM5α by RNAi has little effect on HIV replication,
including mutants expressing a "CsA-dependent" pheno-
type, and TRIM5α knockdown does not relieve the nega-
tive effect of high-dose CypA inhibitors on viral infectivity
[11-13,39,57].
Our results also do not offer support for the possibility
that the increase in infectivity of several viruses observed
in target cells treated with low-dose Debio-025 resulted
from inhibition of the activity of TRIM5α, because
TRIM5α mRNA expression was quite similar for cell types
in which infection with a given virus did or did not dis-
play biphasic dose response curves in response to CypA
inhibitors. CypA binding to the HIV-1 CA increases the
anti-viral activity of rhesus TRIM5α [8,13,27,57,58], and
evidence supporting the idea that CypA binding also
increases interactions between CA and human TRIM5α
and certain human TRIM5α variants has been presented
[27,35,57]. This phenotype has not been observed in all
studies, and following overexpression in feline (CRFK)
cells, human TRIM5α has been found to have greater
inhibitory activity against HIV-1 carrying the G89V muta-
tion, a virus that does not bind CypA, than against wild-
type virus [39,57].
It should be emphasized, however, that the extent that
low-dose Debio-025 increased infectivity and the residual
infectivity observed in cells treated with high-dose Debio-
025 were positively correlated. Furthermore, doses of
Debio-025 that resulted in an increase in viral infectivity
in certain cell types (e.g., U373-X4 cells) overlapped with
those that led to an inhibition of infectivity in other target
cells (e.g., MT4-R5 cells). Taken together, these findings
suggest that the effect of a given dose of Debio-025 onRetrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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viral replication may reflect the relative abundance of two
different putative factors, both of whose effects on viral
infectivity can be modulated by blocking CypA-CA inter-
actions, but in opposite directions. Under these condi-
tions, studies seeking correlations between the expression
of a single factor (e.g., TRIM5α) and responses to a given
dose of a CypA inhibitor may be difficult to interpret,
because differences in the level of expression of the sec-
ond putative factor would also influence the observed
response. Others have suggested that CypA-CA interac-
tions could directly influence a variety of processes,
including roles in maintaining capsid stability, modulat-
ing viral uncoating prior to integration, and protecting
viral cores from cellular restriction factors [8,19-23]. Thus,
activities directly attributable to CypA may represent one
of these factors. Further studies are needed to identify the
additional putative cellular activity (or activities) involved
in the biphasic responses observed here.
Conclusion
In conclusion, our studies indicate that interactions
between host-cell factors and viral proteins coded by gag
have an important effect on viral infectivity, and the stud-
ies evaluating the effect of CypA inhibitors suggest that at
least two distinct cellular activities interacting with the CA
protein may be involved. Thus, the impact on viral infec-
tivity resulting from treating a given cell type with CypA
inhibitors appears to be multifactorial. This reflects both
the relative abundance of two distinct activities, whose
effect on viral infectivity is influenced in opposite direc-
tions by CypA-CA interactions, as well as the intrinsic sen-
sitivity of a given virus to each of these cellular activities.
Methods
Cell culture
HeLa cells, HeLa-derived P4 cells, 293T cells and U373-X4
cells were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal calf serum, 100 U/
ml penicillin G and 100 μg/ml streptomycin (complete
medium). MT4-R5 cells, H9 cells and CEM cells were cul-
tured in similarly supplemented RPMI-1640 medium. For
U373-X4 cells stably expressing CXCR4, the medium also
contained 10 μg/ml puromycin and 100 μg/ml hygromy-
cin B. For P4 cells, the medium also contained 500 μg/ml
G418.
Production of recombinant viruses
The vector pNL4-3-ΔENV-lucR, which expresses Renilla
luciferase in place of Nef and carries a large deletion in
env, has previously been described [59]. To restore the
NL4-3 envelope, the EcoRI – BamHI fragment from pNL4-
3 was ligated into similarly cleaved pNL4-3-ΔENV-lucR,
creating pNL4-3-lucR. To facilitate the construction of
Gag-PR recombinants, a ClaI site was introduced by site-
directed mutagenesis immediately downstream of the
protease region of pNL4-3-lucR as previously described
[60], creating pNL4-3-lucR-XC and pNL4-3-ΔENV-lucR-
XC.
To generate recombinant viruses expressing Gag-PR
sequences from different patients, a protocol analogous to
that described by Zennou et al [60] was used. Briefly,
plasma was obtained from 5 patients followed at Hôpital
Bichat-Claude Bernard, Paris, France who met the follow-
ing criteria: i) infected with a subtype B virus; ii) naïve to
antiretroviral therapy; iii) absence of resistance mutations
in the protease. RNA was purified from plasma, and the
HIV-1 sequence encompassing Gag and protease was
amplified by RT-PCR using the primers ProC and BssHII.
The PCR products were digested with BssHII and ClaI, and
the fragment used to replace the corresponding region
from both pNL4-3-lucR-XC (viruses expressing the NL4-3
envelope) and pNL4-3-ΔENV-lucR-XC (viruses in which
the NL4-3 envelope is deleted). For one patient, two dif-
ferent recombinant viruses were evaluated (NRC3-1 and
NRC3-5). A recombinant virus carrying the pNL4-3 Gag-
PR sequence in which 3 protease resistance mutations
(L10I, G48V and V82A) had been introduced by site-
directed mutagenesis (GPCA) was constructed in a similar
fashion. The resulting plasmids obtained using the pNL4-
3-lucR-XC backbone were used to transfect 293T cells. To
produce VSV pseudotyped env-deleted viruses, the con-
structs obtained using the pNL4-3-ΔENV-lucR-XC back-
bone were cotransfected with a VSV-G expression plasmid
(phCMV-G). Virus-containing culture supernatants were
harvested 48 h after transfection, passed through 0.45 μm
pore size filters, adjusted to 500 ng p24/ml and stored at
-80°C until use.
Infectivity assay
The infectivity of recombinant viruses for different target
cell types was determined by measuring luciferase activity.
P4 cells (9 × 103/well), U373-X4 cells (4.5 × 103/well) or
MT4-R5 cells (2.5 × 104/well) were seeded in black-wall,
clear bottom 96-well plates (Greiner, Frickenhausen, Ger-
many) 24 hours prior to infection. Cells were infected
with serial two-fold dilutions of each virus stock (final
concentrations: 1.56 – 100 ng p24/ml for viruses express-
ing the NL4-3 envelope; 0.156 – 10 ng p24/ml for VSV
pseudotyped viruses) in a final volume of 200 μl culture
medium and incubated at 37°C. After 40 hours, the
supernatant of adherent cells was completely removed
and 50 μl of 1× lysis buffer (Renilla Luciferase kit,
(Promega, Madison, WI) were added. MT4-R5 cells were
centrifuged (1200 × g; 5 min), 150 μl of culture medium
were removed, and 50 μl of 2× lysis buffer were added to
each well. Plates were maintained at room temperature
for 30 min, after which wells were sequentially injected
with 100 μl of luciferase substrate (Promega), and 3 sec-
onds later, light emission (relative light units, RLU) wasRetrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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measured over a two sec interval using a Microlumat
LB96P luminometer (Berthold, Oak Ridge, TN). Each
sample was evaluated in triplicate. RLU were plotted as a
function of amount of p24 used to infect the cells, and
infectivity was defined as the slope [(RLU/2 sec)/(ng p24/
ml)] as determined by linear regression; in this analysis,
each replicate RLU value was treated as an individual
point.
To facilitate the comparison of results obtained in differ-
ent experiments, the infectivity of pNL4-3 was determined
on each 96-well plate, and the infectivity value obtained
for this standard was used to normalize the infectivity of
the other viruses evaluated on the same plate. To do so,
the average infectivity of pNL4-3 for each cell type was
determined (4 independent experiments; 3 96-well
plates/experiment; n = 12), and used to calculate a correc-
tion factor for each plate as follows: [(infectivity for NL4-
3 on the given 96-well plate)/(average infectivity for NL4-
3)]. The infectivity of the other viruses evaluated on the
same plate multiplied by this correction factor is referred
to as normalized infectivity.
Effect of DEBIO-025 and cyclosporine A on viral Infectivity
Debio-025 was kindly provided by Debiopharma
(Lausanne, Suisse). Cyclosporine A was obtained from
Sigma-Aldrich (St. Louis, MO). Both were dissolved in
DMSO (final concentration 10 mM), and stored in aliq-
uots at -80°C. P4 cells (9 × 103/well), U373-X4 cells (4.5
× 103/well), H9 cells (5 × 104/well), MT4-R5 cells and
CEM cells (2.5 × 104/well) were seeded in 96-well plates
24 h prior to infection. Cells were pre-treated with serial
dilutions of Debio-025 or CsA for 15 min and infected
with 100 ng p24/ml (patient-derived recombinant
viruses) or 20 ng p24/ml (NL4-3) of virus in the presence
of the same dilutions of Debio-025 or CsA. After 40 hours
of incubation at 37°C, culture supernatants were
removed, the cells were lysed, and luciferase activity
expressed by the cell lysates was evaluated as described
above. Results are expressed as the percentage of luciferase
activity observed in non-pretreated cells. For studies eval-
uating the effects of CsA, cells were treated with serial
four-fold dilutions (final concentrations 8 nM – 2 μM).
For studies evaluating Debio-025, several dilution
schemes were used in the course of these studies. For the
presentation of the data and statistical analyses, results
obtained for the indicated ranges of concentrations of
Debio-025 were pooled, and are labelled as follows: 5μM
(2–5 μM), 1μM (0.5–1 μM); 200 nM (125–200 nM); 40
nM (30–40 nM); 8 nM (8–10 nM); 1.6 nM (1.6 nM). All
experiments were conducted in triplicate and repeated 6
times (U373-X4, P4, MT4-R5) or three times (CEM, H9).
Neither Debio-025 nor CsA displayed cytotoxic activity
against the target cells over the range of concentrations
used, as evaluated using a MTT assay (Sigma).
Quantification of CypA and TRIM5α mRNA in target cells
Cell suspensions were washed with PBS and mRNA was
extracted from 2 × 106 cells using NucleoSpin RNA II kits
(Macherey-Nagel, Düren, Germany). cDNA synthesis was
performed using random hexamers and Moloney murine
leukemia virus reverse transcriptase (Invitrogen, Carlsbad,
CA), according to the manufacturer's instructions. CypA,
TRIM5α and GAPDH cDNAs were quantified by real-time
PCR using the primers and Taqman probes shown in
Table 2. DNA was diluted 1:10 in 10 mM Tris-HCl (pH
8.0) containing 0.1 mM EDTA and 100 ng/ml salmon
sperm DNA. Reaction mixtures (final volume, 50 μl) con-
tained 1× ABsolute QPCR ROX mix (Abgene, Thermo-
Fisher, Rockford, IL.), 200 nM (each) primer, 100 nM
Taqman probe, and 10 μl of diluted DNA. Amplification
was performed with a 7000 sequence detection system
(Applied Biosystems). Cycling conditions were as follows:
50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles
at 95°C for 15 seconds and 60°C for 1 minute each. To
serve as standards, cDNAs for CypA and TRIM5α were
cloned into pCR-TOPO2.1 vectors (Invitrogen), and a
GAPDH cDNA sequence encompassing that recognized
Table 2: Primers and probes used to quantify viral sequences by real-time PCR
GAPDH
forward primer 5'- ACCCCTGGCCAAGGTCATC
reverse primer 5'- AGGGGCCATCCACAGTCTTC
Probe 5'- (6-Fam)AGGACTCATGACCACAGTCCATGCCA(Tamra)
CypA
forward primer 5'- GGCCGCGTCTCCTTTGA
reverse primer 5'- AATCCTTTCTCTCCAGTGCTCAGA
Probe 5'- (6-Fam)TGCAGACAAGGTCCCAAAGACAGCAG(Tamra)
TRIM5α
forward primer 5'- TGCCTCTGACACTGACTAAGAAGATG
reverse primer 5'- GGGCTAAGGACTCATTCATTGG
Probe 5'- (6-Fam)AAGCTTTTCAACAGCCTTTCTATATCATCGTGTGATA(Tamra)Retrovirology 2009, 6:21 http://www.retrovirology.com/content/6/1/21
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by the GAPDH primers was inserted into the polylinker.
Thus, the same serial dilutions of linearized plasmids
could be used as standards for the quantification of
GAPDH and the gene of interest. Results are expressed as
the number of copies of CypA or TRIM5α mRNA per 1000
copies of GAPDH mRNA.
Western blotting
Cell suspensions were washed two times with PBS, and 3
× 106 cells were pelleted and resuspended in 150 μl of lysis
buffer (1% NP40, 150 mM NaCl, 50 mM of Tris-HCl – pH
7.8). Lysates were cleared by centrifugation (9300 × g; 10
min), and protein content was determined using the Brad-
ford assay (Bio-Rad, Hercules, CA). Cellular proteins were
separated by electrophoresis into 10% SDS-PAGE gels,
and transferred to Immobilion-P membranes (Millipore,
Bedford, BA). The blots were probed sequentially with a
rabbit anti-cyclophilin A antibody (1:1000 dilution, Cell
Signaling Technology, Danvers, MA) and a IRDye
800CW-conjugated donkey anti-rabbit IgG antibody
(1:15000 dilution, Li-Cor Biosciences, Lincoln, NE). The
blots were scanned using an Odyssey Infrared imaging
system, and fluorescence intensity was analysed using
Odyssey application software (version 2.1, Li-Cor).
Lysates from P4 cells were included in each gel, and the
intensities of the CypA bands in the other samples on the
same gel are expressed relative to that observed for P4
cells. The results presented are the mean of 4 independent
experiments, each performed using different cell suspen-
sions.
Statistical analysis
Results are expressed as mean ± SD unless otherwise indi-
cated. Comparisons between groups were performed by
ANOVA. Post test comparisons, performed only if p <
0.05, were made using Bonferroni's Multiple Comparison
Test. Correlations were evaluated using the Pearson test.
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